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Abstract
Background: The proportion of chlamydia tests that are positive (positivity) is dependent on the 
population tested and the test technology used. The way in which changes in these variables might 
affect trends in positivity over time is investigated.
Methods: Data from 15- to 24-year-old women tested for chlamydia in family planning clinics 
participating in the Infertility Prevention Project in the Pacific Northwest, United States (USA 
Public Health Service Region X) during 2003–2010 (n = 590 557) were analysed. Trends in 
positivity and in test, demographic and sexual behaviour variables were identified. Unadjusted and 
adjusted trends in chlamydia positivity were calculated using logistic regression.
Results: The proportion of tests carried out using nucleic acid amplification tests (NAATs) 
increased dramatically during the analysis period in two states. Smaller changes in demographic 
and behavioural characteristics were seen. Controlling for test technology used had the largest 
effect on the trend in testing positive per year, leading to a fall in the calculated odds ratio of 
testing positive from 1.06 to 1.02 in Oregon, and from 1.07 to 1.02 in Idaho. Controlling for other 
variables had minimal effect on chlamydia positivity trends.
Conclusions: Changes in NAAT use had a large effect on observed trends in chlamydia 
positivity over time in the two states where NAATs were introduced during the analysis period. 
While trends in chlamydia positivity may be a useful metric for monitoring chlamydia burden, it is 
important to consider changes in test type when interpreting these data.
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Introduction
During 1993–2011, the Infertility Prevention Project (IPP), a federally funded project to 
prevent infertility, supported increasing access to screening and treatment for Chlamydia 
trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhoea) among young women 
attending family planning, sexually transmitted disease (STD) and other health clinics in the 
United States (US). Funding was provided to state and city health departments and to a 
regional infrastructure, which formed regional advisory committees composed of state STD 
programs, family planning and women’s health programs and public health laboratories. 
Data on women tested for chlamydia were collected in clinics participating in the IPP and 
collated regionally. Data were used to supplement chlamydia case report data to monitor 
trends in chlamydia and for program evaluation and quality improvement activities at a 
clinic, state and regional level.1
Among 15- to 24-year-old women tested in family planning clinics participating in the IPP, 
the proportion of chlamydia tests that were positive (hereafter ‘positivity’) increased during 
2000–2011.1 However, this does not necessarily mean that the population prevalence of 
chlamydial infection (defined as the proportion of the general population who are infected 
with chlamydia) increased during this period. Positivity is dependent on the population 
tested and test technology used,2–4 so does not equate directly to true population prevalence. 
Consequently, observed trends in chlamydia positivity may be due to changes in the 
characteristics of the population tested at different time points,3 or changes in the type of 
diagnostic test used1 rather than changes in the underlying burden of disease in the 
population. Interpreting observed trends without consideration of changes in the population 
tested over time could lead to erroneous conclusions about the changing burden of disease 
over time. Satterwhite et al. reported that, after accounting for changes in clinic attendee 
demographics (age, race, geography) and test technology, positivity among 15- to 24-year-
old women tested in family planning clinics participating in the IPP between 2004 and 
20085 remained stable, contrary to national trends in crude positivity. However, as limited 
information was available at the national level, they were unable to account for other, 
potentially important, changes in the population screened that could affect the positivity 
among those tested. For example, they did not account for changes in the proportion of tests 
conducted among symptomatic women or among those with a recent positive test.
Understanding what factors affect observed trends in positivity is critical to interpreting 
trends in existing IPP data, as well as for identifying the potential utility of different data 
items for use in future surveillance systems. In order to investigate the impact of changes in 
the population of clinic attendees on observed trends in chlamydia positivity, we analysed 
data from young women tested for chlamydia in family planning clinics that participated in 
the IPP in the United States’ Pacific Northwest [US Public Health Service (USPHS) Region 
X], an area that collected enhanced data elements not available in most other USPHS 
regions. We aimed to identify to what extent changes in test, demographic or behavioural 
characteristics of clinic attendees tested for chlamydia between 2003 and 2010 might have 
affected the observed trends in positivity over the analysis period.
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Methods
Data sources
We analysed IPP chlamydia test records from Region X (comprising the states of 
Washington, Idaho, Oregon and Alaska) female family planning clients aged 15–24 years, 
for the period 2003–2010. Equivocal test results were excluded.
Test-level data were collected and collated regionally. The following variables were 
available: (1) test result; (2) year of test; test technology [nucleic acid amplification test 
(NAAT) or non-NAAT]; (3) patient age in years; race/ethnicity (non-Hispanic white or 
other); (4) reported abnormal discharge; (5) reported exposure to chlamydia; having more 
than one sexual partner in the last 60 days; (6) having a new sexual partner in the last 60 
days; and (7) reason for test (re-screen after positive test or other). A test was considered to 
be a re-screen if the patient reported the reason for visit as ‘re-screen’ or if they had a known 
chlamydia diagnosis in the previous 12 months (self-reported or identified in the IPP 
dataset).
Exploring the effect of changes in characteristics on the observed trends in positivity
We reported test, demographic and behavioural characteristics for tests over time, stratified 
by state. We used logistic regression to identify the trend in chlamydia positivity during 
2003–2010. Year was included as a continuous variable, with test result (positive/negative) 
as the outcome variable. The annual percentage observed change in positivity was estimated 
using the odds ratio (OR) of testing positive for chlamydia per additional test year. A series 
of bivariable models were constructed that included test result as the outcome variable and 
year and one other variable as predictors (e.g. year and age, year and race/ethnicity, year and 
exposure to chlamydia). We compared the estimated annual observed change in positivity 
with the estimated change resulting from the different models in order to explore whether 
there was any evidence that changes in the available demographic and behavioural variables 
or in test technology had any effect on the observed trends in chlamydia positivity.
All variables were then included in a multivariable model to determine the combined effect 
on observed trends in positivity. In the multivariable model, having more than one sex 
partner in the previous 60 days and having a new sex partner in the previous 60 days were 
combined into a single measure (reporting either or both vs reporting neither) to avoid 
collinearity.
Sensitivity analysis to explore the potential impact of test technology on positivity trends
Inclusion of test type (NAAT/non-NAAT), as described above, indicates that the test type has 
a substantial impact on the observed trend in positivity. However, the model predictions of 
positivity would not reflect the true proportion of those tested who had an infection, as this 
would not fully account for sensitivity and specificity of tests used. We therefore carried out 
sensitivity analyses of data from Idaho and Oregon, where substantial changes in test 
technology occurred during the analysis period. A logistic regression model correcting for 
sensitivity and specificity of tests used was constructed for Idaho and Oregon data using the 
‘logitem’ command in Stata.6 Sensitivity and specificity estimates from a previous review of 
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chlamydia diagnostic tests7 were applied for each of the tests, or package inserts for tests not 
included in the review.8–10 In order to explore potential error in sensitivity and specificity 
estimates arising from imperfect gold standards for chlamydia testing,11 alternative 
scenarios were modelled using combinations of the reported sensitivity 5 percentage points, 
and specificity ±1 percentage point for the main tests used during the period in each state 
(Probe and TC-TMA in Idaho; signal amplification and TC-TMA in Oregon). The resulting 
predicted positivities from logistic regression models were plotted against the observed data 
(Fig. 4).
All statistical analyses were performed using Stata version 12.0 (StataCorp, College Station, 
Texas, USA).
Results
A total of 590 557 tests among 15- to 24-year-old women were included. The median age 
was 20 years and 60% of tests came from women aged 20–24 years. The majority of tests 
were among women of non-Hispanic white race/ethnicity (71%). Washington and Oregon 
contributed the highest number of tests (45% and 36%, respectively). Overall, 6.1% of tests 
were positive. Nineteen per cent reported a new sexual partner in the last 60 days and 8.6% 
reported more than one sexual partner in the last 60 days (Table 1). During 2003–2010, the 
total number of tests per year conducted in Region X IPP family planning declined 20% 
from 78 352 (2003) to 62 755 (2010). The majority of this decline was due to a fall in tests 
reported in Washington State during 2003–2007 (Fig. 1).
Trends in reported characteristics of clinic attendees and the use of NAATs
Trends in the reported demographic and behavioural characteristics of those tested, and in 
the use of NAATs during the study period, varied by state. In Washington (Fig. 2a, b), the 
proportion of women tested who reported having either multiple sex partners or a new sex 
partner declined slightly from 2003 to 2006, and then increased slightly up to 2010. The 
proportion of tests among females of non-white, non-Hispanic race increased from 2003 to 
2007, and then remained stable. Other characteristics remained relatively stable in this state. 
In Oregon (Fig. 2c, d), there was a steady decline in the proportion of tests among 15- to 19-
year-olds, from 43% in 2003 to 30% in 2010. The proportion reporting abnormal discharge 
declined from 12% to 8%, but other variables remained stable. In Idaho (Fig. 2e, f), notable 
changes included a fall in the proportion of tests among 15- to 19-year-olds from 2003 to 
2005, an increase in the proportion of tests where multiple or new partners in the previous 60 
days were reported, and an increase in the proportion of tests among people of non-white, 
non-Hispanic race. Demographic and behavioural variables fluctuated more in Alaska (Fig. 
2g, h), which was likely due to the smaller sample size from this state.
In Idaho and Oregon, the proportion of tests that were conducted using NAATs increased 
substantially from <6% in 2003–2004 to 99% from 2006 onward in Idaho (Fig. 2e), and 
from <1% between 2003 and 2008, to 100% in 2010 in Oregon (Fig. 2c). Washington and 
Alaska reported NAAT use in excess of 98% throughout the period (Fig. 2a, d).
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Impact of changes in characteristics of clinic attendees and the use of NAATs on state-
specific trends in positivity
Overall, chlamydia positivity was 6.1% and varied by state, ranging from 4.8% in Oregon to 
8.6% in Alaska. An increase in the proportion testing positive (unadjusted for other factors) 
was observed in Idaho and Oregon, from 5.5% in 2003 to 7.2% in 2010 in Idaho (OR 1.07, 
95%CI 1.05–1.08) and 4.2% to 6.4% in Oregon (OR 1.06, 95%CI 1.05–1.07) (Fig. 2). 
Observed positivity remained relatively stable in Washington during this period (OR 0.99, 
95%CI 0.99–1.00), and no consistent trend was observed in Alaska (OR 1.01, 95%CI 0.99–
1.03).
The adjusted ORs of testing positive per year are shown in Fig. 3. Adjusted ORs are reported 
where each demographic and behavioural variable was included with year in the bivariable 
models (indicated by black diamonds); for the multivariable analysis, all variables were 
included (indicated by red diamonds).
In both the bivariable and multivariable analyses, all variables were statistically significantly 
associated with testing positive (data not shown). In Oregon and Idaho, controlling for test 
technology had the largest effect on the odds of testing positive per year. In Oregon, a 6% 
annual increase in positivity was observed before adjustment, whereas after controlling for 
test technology, the annual estimated increase in positivity fell to 2% (AOR 1.02, 95%CI 
1.01–1.03). In Idaho, the unadjusted trend showed a 7% annual increase, which decreased to 
a 2% annual increase after adjustment for test type (AOR 1.02, 95%CI 1.00–1.04). 
Negligible differences were seen between unadjusted and adjusted ORs of testing positive 
per year when variables other than test technology were included in the bivariable models.
In the multivariable model, adjustment made a substantial difference to the OR of testing 
positive per year in Idaho. The adjusted OR (indicated by the red diamond in Fig. 3) was 
1.02, whereas the unadjusted OR (indicated by the open diamond in Fig. 3) was 1.07. Most 
of this difference was accounted for by controlling for test technology.
The ORs from multivariable models were more similar to the unadjusted ORs in Oregon 
(AOR 1.04, OR 1.06).
Sensitivity analysis to explore potential impact of test technology on positivity trends
Figure 4 shows the observed and model-predicted positivities for a range of scenarios, 
adjusting for estimated sensitivity and specificity of tests used in Idaho and Oregon. 
Applying the literature-derived point estimates resulted in a sensitivity- and specificity-
adjusted OR of testing positive per year of 1.04 (95% CI 1.03–1.06) in Idaho (Fig. 4a) and 
1.12 (95%CI 1.10–1.14) in Oregon (Fig. 4b). Depending on the combination of sensitivity 
and specificity estimates applied to the two main tests used during the period, the sensitivity- 
and specificity-adjusted OR ranged from 0.99 (95%CI 0.97–1.00) to 1.12 (95%CI 1.10–
1.14) in Idaho and 1.04 (95%CI 1.02–1.05) to 1.30 (95%CI 1.27–1.32) in Oregon.
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Discussion
Our analysis of data from young women tested for chlamydia in family planning clinics that 
participated in the IPP in the Pacific Northwest showed that changes in NAAT use over time 
had a substantial effect on the observed trends in positivity in the two states where NAATs 
were introduced during the analysis period. There was some variation in the reported 
demographic and behavioural characteristics of the women tested in family planning clinics 
as part of the IPP over time. However, the observed differences made relatively little 
difference to the observed trend in positivity.
By incorporating patient-level factors not available in the national IPP dataset, we could 
explore the impact of changes in demographics and reported sexual behaviour over time on 
observed trends in positivity. Our analyses were, however, limited to variables collected 
routinely. It is possible that the population changed in ways that were not captured by the 
available variables, either because some risk factors were not measured or because the 
categories available were not sufficiently detailed. For example, we categorised individuals 
according to whether they reported a new sexual partner in the last 60 days. We could not 
apply more precise categories that would have distinguished those who had one new partner 
from those who had many more. In Alaska and Washington (where NAATs were used across 
the period), the proportion of those tested who reported an abnormal discharge changed over 
time. This may indicate variations in testing practices in clinics, with increased/decreased 
testing among asymptomatic patients. It was not possible to investigate this further as data 
on variations in testing practices over time were not available. However, we note that 
chlamydia screening of young women was regularly stressed as part of semi-annual Region 
X IPP program meetings, which may have contributed to increases in testing among 
asymptomatic women. Positivity trends in Alaska closely followed patterns seen in the 
percentage reporting abnormal discharge, but in neither Washington or Alaska did adjusting 
for abnormal discharge have a notable effect on overall conclusions about trends in positivity 
over the period studied. A further limitation is that clinics that contributed data to the IPP 
varied over time. As such, trends in positivity may have varied if our analysis had been 
limited to a set of clinics that had consistently contributed data over the analysis period. 
However, as our analysis was designed to look at factors affecting trends in positivity, rather 
than the absolute trends in infection, we don’t consider this likely to have substantially 
affected our findings.
Increasing use of NAATs had the most effect on the observed trends in positivity. It is well 
documented that NAATs are considerably more sensitive than other available chlamydia 
tests, and that changes in test technology should be considered when calculating and 
interpreting trends in chlamydia positivity.2,4 However, national reports of positivity trends 
have not been consistently adjusted for changes in NAAT use over time.1 Our analysis adds 
to existing evidence demonstrating the importance of interpreting chlamydia positivity or 
case report trends in the context of changes in test type. Our sensitivity analyses of predicted 
positivity with varying test performance characteristics further demonstrates the potential 
impact of test technology, as the observed trend in positivity was dependent on the 
assumptions about sensitivity and specificity of the tests used. Further work is needed to 
fully understand the impact of assumptions on correction for test sensitivity and specificity.
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We documented variation in trends by state within Region X. While it is possible that 
changes in the tested population affected trends in different states, it is also feasible that 
there were different underlying trends in population prevalence in these states. Unadjusted 
reports of positivity trends at a national or regional level may be of limited value for local 
public health planning, as these are likely to mask substantial variation between states or 
within states across counties, municipalities or family planning agencies.
The effect of changes in the population tested on observed positivity depends on the extent 
to which client characteristics are associated with positivity and the variation in 
characteristics over time. In our analysis, although the available demographic and 
behavioural variables were associated with testing positive, they did not vary enough over 
time to have a substantial impact on the measured positivity trend. This is consistent with a 
previous analysis of chlamydia positivity in Region X for the period 1997 to 2004.12 In other 
states, clinical settings or time periods, the tested population might change more over time. 
For example, changes in selective screening protocols, the availability of clinical services in 
the area3 or in the underlying risk behaviours of the eligible population may occur. More 
significant changes would likely have a greater impact on positivity trends. To illustrate this, 
we investigated two hypothetical scenarios. Using the distribution of reported characteristics 
observed in Region X in 2003 as a baseline, we estimated the positivity following a 5% or 
10% annual increase in the number of women tested who had each characteristic (Fig. 5). 
For example, a relative increase of 5% per year in the proportion of the tested population 
reporting either multiple or new sexual partners in the last 60 days would lead to a 7% 
overall increase in observed positivity during 2003–2010 (rising from 6.0% to 6.4%) (Fig. 
4). Similarly, a relative increase of 5% per year of the population tested who were aged 15–
19 years old would result in a 5% overall increase in observed positivity (rising from 6.0% 
to 6.3%) (Fig. 5). These changes would be solely due to the selection effects of changes in 
the population tested (i.e. with no change in the population prevalence). The observed 
increase in positivity would, of course, be higher with greater changes in the characteristics 
of the population tested. This is important because many programs do not collect, or do not 
routinely use, data on demographic and behavioural risk factors, and may therefore overlook 
the impact of changes in either the risk profile of clinic attendees or in the population offered 
testing on trends in crude positivity.
Given the availability of information on numbers of tests and test results, women attending 
family planning services remain a useful sentinel population to indicate chlamydia burden in 
the US – albeit in a selected population – and trends in positivity may be a useful metric. 
However, as trends in chlamydia positivity are used to inform and evaluate chlamydia 
screening programs,13–15 understanding the potential limitations of these data, and 
appreciating the context in which they are collected, is essential. In order to maximise the 
utility of surveillance data, patient-level demographic and behavioural data and information 
on test uptake and test technology within any clinical setting should be collected and 
incorporated into positivity analyses. As clinics have embraced electronic health record 
systems in recent years, monitoring client characteristics and risk factors may be more 
readily attainable. The choice of variables should be steered by the association between each 
factor and positivity, the likelihood of obtaining accurate measurement of each variable, the 
feasibility of data collection and program and policy goals.
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Fig. 1. 
Number of chlamydia tests among women aged 15–24 years who were tested in family 
planning clinics in Region X and reported to the Infertility Prevention Project (2003–2010).
Woodhall et al. Page 9
Sex Health. Author manuscript; available in PMC 2019 December 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
(a–h) Test, demographic and behavioural characteristics and chlamydia positivity among 
women aged 15–24 years tested for chlamydia in Region X family planning clinics reported 
to the Infertility Prevention Project (2003–2010).
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Fig. 3. 
Unadjusted and adjusted (bivariable and multivariable) odds ratios of testing positive per 
year among women aged 15–24 years who were tested in family planning clinics in Region 
X and reported to the Infertility Prevention Project (2003–2010). *More than one and/or at 
least one new sexual partner in the previous 60 days. (◊), Unadjusted ORs; (✦) show results 
for models where year and the specified variable were included; Closed red diamonds (✦) 
show results for multivariable models where year and all other variables were included. 
Whiskers show 95% confidence interval.
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Fig. 4. 
Observed and predicted positivity with and without adjustment for estimated sensitivity and 
specificity of diagnostic tests. (a) Idaho, (b) Oregon. (●) show the observed positivities in 
each year. Solid and dashed lines show positivities predicted from logistic regression 
models, with year entered as a continuous variable. The solid line presents predicted 
positivity without adjustment for sensitivity or specificity of the tests. Dashed lines present 
predicted positivities from sensitivity- and specificity-adjusted models, using estimates 
derived from the literature. Scenarios labelled [b] to [e] show model scenarios using 
combinations of the reported sensitivity ± 5 percentage points and specificity ±1 percentage 
point for the main tests used during the period in each state (in Idaho the Gen-Probe Aptima 
Combo 2 and Gen-Probe PACE 2 accounted for >99% of all tests. In Oregon the Gen-Probe 
Aptima Combo 2 and Digene, Hyprid capture 2 CT/GC test accounted for 92% of all tests). 
[a] Linear trend, sensitivity and specificity point estimates adjusted. [b] Minimum 
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sensitivity, maximum specificity for each test. [c] Maximum sensitivity, minimum specificity 
for each test. [d] Minimum sensitivity and maximum specificity applied to Gen-Probe PACE 
2(Idaho)/Digene, Hyprid capture 2(Oregon); Maximum sensitivity and minimum specificity 
applied to Gen-Probe Aptima Combo 2. [e] Maximum sensitivity and minimum specificity 
applied to Gen-Probe PACE 2(Idaho)/Digene, Hyprid capture 2(Oregon); Minimum 
sensitivity and maximum specificity applied to Gen-Probe Aptima Combo 2.
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Fig. 5. 
(a, b) Hypothetical scenarios regarding changes in observed proportion testing positive for 
chlamydia, given changes in the population tested, using 2003 Region X Infertility 
Prevention Project data from family planning clinics as baseline values. (a) Scenario 1, a 5% 
increase per year in proportion with each characteristic among the population tested. (b) 
Scenario 2, a 10% increase per year in proportion with each characteristic among the 
population tested.
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